Physician profile
Robert Pecha
NPI 1619918133
$12,666.91
in general payments reported to CMS, 2019-2025
38 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $698 · 2021: $981 · 2022: $1,345 · 2023: $1,707 · 2024: $2,796 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,459 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,458.57 |
| Education | $108.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,222.52 | 2019-2025 | |
| Janssen Biotech, INC. | $1,580.10 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,030.49 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $1,025.67 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $977.35 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $428.79 | 2019-2025 | |
| Madrigal Pharmaceuticals | $416.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $391.75 | 2019-2025 | Sucraid |
| Gilead Sciences, INC. | $286.08 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $272.06 | 2023-2025 | Dupixent |
| Celgene Corporation | $250.48 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $220.89 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $166.14 | 2021-2023 | |
| Allergan, INC. | $157.26 | 2019 | |
| Intercept Pharmaceuticals, INC. | $137.50 | 2022-2024 | Ocaliva |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $125.22 | 2025 | Iqirvo |
| Boston Scientific Corporation | $122.05 | 2024-2025 | Orcapod, Resolution 360 Clip, Koala |
| Aimmune Therapeutics, INC. | $101.28 | 2025 | Vowst |
| Daiichi Sankyo INC. | $87.16 | 2021-2023 | Injectafer |
| Braintree Laboratories, INC. | $78.29 | 2019-2024 | Sutab |
| Ironwood Pharmaceuticals, INC | $63.64 | 2019-2022 | |
| Olympus America INC. | $55.45 | 2019 | |
| Ardelyx, INC. | $49.74 | 2022 | |
| Phathom Pharmaceuticals, INC. | $48.03 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $46.43 | 2019-2021 | |
| Lilly USA, LLC | $45.10 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $37.37 | 2023 | Cologuard Collection Kit |
| Fujifilm Healthcare Americas Corporation | $37.07 | 2025 | |
| Organon LLC | $34.46 | 2023-2024 | Hadlima |
| Alfasigma USA, INC. | $28.34 | 2020-2021 | |
| Biocon Biologics INC | $27.53 | 2025 | Yesintek |
| Ucb, INC. | $21.94 | 2019 | |
| Vivus LLC | $21.09 | 2024 | Pancreaze |
| Celltrion USA INC. | $18.43 | 2024 | Zymfentra |
| Shionogi INC | $15.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.78 | 2023 | Cyltezo |
| Medline Industries LP | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.